Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.4.21.60 - Scutelarin

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acute Kidney Injury
Fibrinogenolytic and procoagulant activities in the hemorrhagic syndrome caused by Lonomia obliqua caterpillars.
Antiphospholipid Syndrome
Management of lepirudin therapy for a patient with antiphospholipid antibody syndrome using the whole blood ecarin clot time and activated partial thromboplastin time.
Cardiovascular Diseases
Medical consequences of obesity.
Disseminated Intravascular Coagulation
Cloning of a prothrombin activator-like metalloproteinase from the West African saw-scaled viper, Echis ocellatus.
Disseminated intravascular coagulation following Echis carinatus venom in dogs: effects of a synthetic thrombin inhibitor.
Ecarin test in diagnosis of dicoumarol therapy, liver diseases and DIC.
Effects of lopap on human endothelial cells and platelets.
Fibrinogenolytic and procoagulant activities in the hemorrhagic syndrome caused by Lonomia obliqua caterpillars.
In vivo characterization of Lopap, a prothrombin activator serine protease from the Lonomia obliqua caterpillar venom.
The cardiovascular and haematological effects of purified prothrombin activator from the common brown snake (Pseudonaja textilis) and their antagonism with heparin.
Hypertension
Medical consequences of obesity.
Infections
Vibrio vulnificus secretes a broad-specificity metalloprotease capable of interfering with blood homeostasis through prothrombin activation and fibrinolysis.
Liver Diseases
Determination of plasma prothrombin levels by a novel Ca2+-dependent prothrombin activator (CA-1) in patients with chronic liver diseases.
Ecarin test in diagnosis of dicoumarol therapy, liver diseases and DIC.
Neoplasms
Effects of lopap on human endothelial cells and platelets.
Obesity
Medical consequences of obesity.
Spinal Cord Injuries
Deficiency within the extrinsic prothrombin activator system in patients with acute spinal cord injury.
Thrombocytopenia
A quick assay for monitoring recombinant hirudin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II : adaptation of the ecarin clotting time to the act II device.
Hirudin monitoring using the TAS ecarin clotting time in patients with heparin-induced thrombocytopenia type II.
Successful use of recombinant hirudin and its monitoring by ecarin clotting time in patients with heparin-induced thrombocytopenia undergoing off-pump coronary artery revascularization.
The use of ecarin chromogenic assay and prothrombinase induced clotting time in the monitoring of lepirudin for the treatment of heparin-induced thrombocytopenia.
Use of ecarin clotting time (ECT) with lepirudin therapy in heparin-induced thrombocytopenia and cardiopulmonary bypass.
[Use of ecarin clotting time in whole blood for monitoring recombinant hirudine treatment during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia]
Thrombosis
Comparative proteomic analysis of the venom of the taipan snake, Oxyuranus scutellatus, from Papua New Guinea and Australia: Role of neurotoxic and procoagulant effects in venom toxicity.
Ecarin Clotting Time: a predictive coagulation assay for the antithrombotic activity of argatroban in the rat.
In vivo characterization of Lopap, a prothrombin activator serine protease from the Lonomia obliqua caterpillar venom.
Properties of biological and biochemical effects of the Iranian saw-scaled viper (Echis carinatus) venom.
Venous Thrombosis
Ecarin Clotting Time: a predictive coagulation assay for the antithrombotic activity of argatroban in the rat.
Inhibition of experimental arterial and venous thrombosis by ecarin, a defibrinating enzyme.